Table 1

Markers of ovarian reserve in SLE

StudyType of studyNo. CYC-untreated (CYC−) patients with SLEMeasure of ovarian reserve AMH AFC OVResultsComments
Gasparin et al9Case-control40Comparable AMH levels in SLE/CYC− and control groups.
Gao et al10Case-control40AMH of SLE/CYC− group was significantly lower than in control group (p<0.001).AMH was negatively correlated with disease activity (SLEDAI) (p=0.033).
AMH concentration in SLE/CYC− group with normal menstruation was higher than SLE/CYC− group with abnormal menstruation (p<0.001).
Angley et al39Cohort68SLE/CYC− women were 1.5–1.6 times more likely to have AMH levels <1.0 ng/mL (PR 1.62, 95% CI 0.93 to 2.82) and AMH levels below the 25th percentile as compared with women without SLE (PR 1.55 (95% CI 0.97 to 2.47)).
Lawrenz et al38Cross-sectional33AMH of SLE/CYC− group was significantly lower than in control group (p<0.05).There was no correlation between AMH and illness duration or disease activity (SLEDAI).
Ulug et al40Cohort20AFC and OV of SLE/CYC− group were significantly lower than in control group (p<0.001, p=0.006, respectively).Menstrual irregularities significantly higher in SLE/CYC− group than in control group.
Di Mario et al41Cross-sectional86Comparable AMH levels in SLE and control groups.
  • AFC, antral follicle count; AMH, anti-Müllerian hormone; CYC, cyclophosphamide; OV, ovarian volume; SLEDAI, SLE Disease Activity Index.